In the present study, the degradation effect on FLT3 itself, along with the significant anti-AML effects of IHCH9033 monotherapy, suggests that combining IHCH9033 with FLT3i could enhance the inhibition of FLT3 and downstream signaling, leading to the markedly synergistic antitumor activity. Here, FLT3 is linked to acute myeloid leukemia.